LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Initial Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 112 Patients From Veracruz in Southeastern Mexico.

    Remes-Troche, Jose María / Ramos-de-la-Medina, Antonio / Manríquez-Reyes, Marisol / Martínez-Pérez-Maldonado, Laura / Lara, Elizabeth Lagunes / Solís-González, María Antonieta

    Gastroenterology

    2020  Volume 159, Issue 3, Page(s) 1179–1181

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Liver ; Mexico ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-21
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2020.05.055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui V Zs.44: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 572: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Initial Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 112 Patients From Veracruz in Southeastern Mexico

    Remes-Troche, Jose María / Ramos-de-la-Medina, Antonio / Manríquez-Reyes, Marisol / Martínez-Pérez-Maldonado, Laura / Lara, Elizabeth Lagunes / Solís-González, María Antonieta

    Gastroenterology

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #348813
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: Initial Gastrointestinal Manifestations in Patients with SARS-CoV-2 in 112 patients from Veracruz (Southeastern Mexico)

    Remes-Troche, Jose María / Ramos-de-la-Medina, Antonio / Manríquez-Reyes, Marisol / Martínez-Pérez-Maldonado, Laura / Lara, Elizabeth Lagunes / Solís-González, María Antonieta

    Gastroenterology

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32446696
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico).

    Remes-Troche, Jose Maria / Ramos-de-la-Medina, Antonio / Manriquez-Reyes, Marisol / Martinez-Perez Maldonado, Laura / Solis-Gonzalez, Maria Antonieta / Hernandez-Flores, Karina / Vivanco-Cid, Hector

    medRxiv

    Abstract: ... Introduction/Aim: ... Recent studies have shown that seroprevalence is quite variable depending on the country, the population and the time of the pandemic in which the serological tests are performed. Here, we investigated the prevalence of IgG ... ...

    Abstract Introduction/Aim: Recent studies have shown that seroprevalence is quite variable depending on the country, the population and the time of the pandemic in which the serological tests are performed. Here, we investigated the prevalence of IgG antibodies against SARS-CoV-2 in a population living in Veracruz City, Mexico. Methods: From of June 1 to July 31, 2020, the consecutive adult patients that attended 2 ambulatory diagnostic private practice centers for testing were included. Samples were run on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG assay. The main outcome was seroprevalence. Demographics, previous infection to SARS-CoV-2 (according to a previous positive polymerase-chain reaction nasopharyngeal swab), self-suspicious of virus of infection (according to have in the previous 4 weeks either fever, headache, respiratory symptoms but not a confirmatory PCR) or no having symptoms were also evaluated. Results: A total of 2174 subjects were tested, included 53.6% women (mean age 41.8, range 18-98 years). One thousand and forty-one (52.5%) subjects were asymptomatic, 722 (33.2%) had suspicious of infection and 311 (14.3%) had previous infection. Overall, 642 of 2174 (29.5% [95% CI 27.59%-31.47%]) of our population were seropositive. Seropositivity among groups was 21.3% in asymptomatic, 23.4% in self-suspicious patients and 73.9% in previous infection patients. Conclusions: We found one of the highest seroprevalences reported for SARS-CoV-2 worldwide in asymptomatic subjects (21.3%) as well in subjects with self-suspicious of COVID-19 (23.4%). The number of infected subjects in our population is not encouraging and it should be interpreted with caution.
    Keywords covid19
    Language English
    Publishing date 2020-10-21
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.10.19.20215558
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study.

    Durán-Méndez, Alejandro / Aguilar-Arroyo, Alma Delia / Vivanco-Gómez, Emiliano / Nieto-Ortega, Eduardo / Pérez-Ortega, Daniela / Jiménez-Pérez, Cristian / Hernández-Skewes, Karla Y / Montiel-Bravo, Guillermo / Roque-Reyes, Oscar J / Romero-Lechuga, Fernanda / Medina-Santos, Diana / Oriana-Román, Perla / Flores-Hernández, Jorge Rafael / Méndez-Coca, Juan Daniel / Montaño-Olmos, Daniela / Farfán-Lazos, Karla Cecilia / Tobón-Cubillos, Miranda / Viveros-Hernández, América / Sevilla-Castillo, Fernando /
    Hernández-Romero, Ángel Raúl / Ortega-Rodríguez, Shannat / Jardínez-Vera, Aldo Christiaan / Solís-González, María Antonieta / de la Medina, Antonio Ramos / Pérez-Maldonado, Laura Martínez / Lagunes-Lara, Elizabeth / Cova-Bonilla, Miguel / Peón, Alberto N

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 19728

    Abstract: Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to ... ...

    Abstract Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400-800 mg or > 800 mg), either at the viral (1-7 days post-symptom onset), early inflammatory (8-15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37-4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4-15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400-800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; C-Reactive Protein/analysis ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/pathology ; Dose-Response Relationship, Drug ; Fibrin Fibrinogen Degradation Products/analysis ; Humans ; Odds Ratio ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Survival Analysis ; Survival Rate
    Chemical Substances Antibodies, Monoclonal, Humanized ; Fibrin Fibrinogen Degradation Products ; fibrin fragment D ; C-Reactive Protein (9007-41-4) ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2021-10-05
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-99291-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top